Caribou Logo.png
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
May 16, 2022 16:05 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
ShapeTX_Logo_BLUE.png
Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting
May 12, 2022 08:00 ET | Shape Therapeutics, Inc.
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics® Inc. the RNA technology company advancing programmable medicine, today announced new data from its RNAfix®, RNAskipTM and AAVidTM...
Otonomy, Inc. Logo
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
May 12, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Freeline_Logo_Red_RGB.jpg
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
May 02, 2022 17:10 ET | Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2022 16:45 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Autolus-Logo_Bright_Blue-–-RGB.png
Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022 
May 02, 2022 16:31 ET | Autolus Therapeutics plc
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Caribou Logo.png
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
May 02, 2022 16:30 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the...
new-pharma300x111.jpg
Informa Pharma Intelligence and The American Society of Gene & Cell Therapy (ASGCT) Launches Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report
April 28, 2022 12:00 ET | Informa Business Intelligence
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and The American Society of Gene & Cell Therapy...
Otonomy, Inc. Logo
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
May 14, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
May 13, 2021 07:00 ET | uniQure Inc.
~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~ ~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ...